Approvals/TGA/RYBREVANT amivantamab 350 mg/7 mL concentrate for solution for infusion vial

Approved

STANDARD

RYBREVANT amivantamab 350 mg/7 mL concentrate for solution for infusion vial

Janssen-Cilag Pty Ltd🇦🇺 Therapeutic Goods Administration

Approval Id: 25b3fbf7836f259f
Product Name: RYBREVANT amivantamab 350 mg/7 mL concentrate for solution for infusion vial
Artg Id: 376832
Artg Name: RYBREVANT amivantamab 350 mg/7 mL concentrate for solution for infusion vial
Sponsor: Janssen-Cilag Pty Ltd
Company Detail Path: /organization/janssen-cilag-pty-ltd
Artg Date: 2022-12-01
Registration Type: Medicine
Therapeutic Good Type: Medicine
Licence Status: A
Licence Category: RE
Consumer Medicine Info: https://medical-cdn.nocode.com/drug_tga/6148ba452d923144a312670b54ec2de8.pdf
Product Information: https://medical-cdn.nocode.com/drug_tga/13f4c296d944cc1d3fd407a9bc155cb3.pdf

Approved

Agency

TGA

Country

🇦🇺

Approval Date

May 30, 2025

Approval ID

25b3fbf7836f259f

Type

Standard